FASEB J. Avanti Polar Lipids
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by SMITH, U.
Right arrow Articles by SVALSTEDT, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by SMITH, U.
Right arrow Articles by SVALSTEDT, B.
(The FASEB Journal. 2001;15:215-220.)
© 2001 FASEB

Thiazolidinediones (PPAR{gamma} agonists) but not PPAR{alpha} agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes1

ULF SMITH2, SILVIA GOGG, AINO JOHANSSON, TORBJÖRN OLAUSSON, VICTORIA ROTTER and BIRGITTA SVALSTEDT

The Lundberg Laboratory for Diabetes Research, Department of Internal Medicine, Goteborg University, Sahlgrenska University Hospital, S-413 45 Goteborg, Sweden

2Correspondence: The Lundberg Laboratory for Diabetes Research, Department of Internal Medicine, Sahlgrenska University Hospital, Guldhetsgatan, Gothenburg S-413 45 Goteborg, Sweden. E-mail. ulf.smith{at}medic.gu.se

Thiazolidinediones (TZD) improve insulin sensitivity in human as well as in different animal models of insulin resistance and Type 2 diabetes. However, no clear link to the insulin signaling events has been identified. Using differentiated 3T3-L1 adipocytes, we found that TZD rapidly and markedly increased IRS-2 gene expression. This effect was specific for PPAR{gamma} agonists and was not seen with PPAR{alpha} agonists. It was rapidly induced (within 4 h) and maintained throughout the observation period of 48 h. It was also concentration dependent (EC50 ~50 nM) and not inhibited by cycloheximide, suggesting a direct effect on the IRS-2 promoter. There was no evidence that TZD altered IRS-2 mRNA stability, supporting that the increased mRNA levels were due to an increased gene transcription. IRS-2 protein expression was increased ~30% after 48 h and ~50% after 96 h. No effects of TZD were seen on IRS-1, PKB/Akt, or GLUT4 gene expression. TZD also increased IRS-2 mRNA levels in cultured human adipose tissue. These data show the first direct link between TZD and a critical molecule in insulin’s signaling cascade in both 3T3-L1 and human adipocytes, and indicate a novel mode of action of these compounds.—Smith, U., Gogg, S., Johansson, A., Olausson, T., Rotter, V., Svalstedt, B. Thiazolidinediones (PPAR{gamma} agonists) but not PPAR{alpha} agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes.


Key Words: insulin signaling • insulin action • gene transcription • IRS-2 • PPAR




This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
M Udelhoven, U Leeser, S Freude, M M Hettich, M Laudes, J Schnitker, W Krone, and M Schubert
Identification of a region in the human IRS2 promoter essential for stress induced transcription depending on SP1, NFI binding and ERK activation in HepG2 cells
J. Mol. Endocrinol., February 1, 2010; 44(2): 99 - 113.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Murdolo, A. Hammarstedt, M. Schmelz, P.-A. Jansson, and U. Smith
Acute Hyperinsulinemia Differentially Regulates Interstitial and Circulating Adiponectin Oligomeric Pattern in Lean and Insulin-Resistant, Obese Individuals
J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4508 - 4516.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
H. Basciano, A. Miller, C. Baker, M. Naples, and K. Adeli
LXR{alpha} activation perturbs hepatic insulin signaling and stimulates production of apolipoprotein B-containing lipoproteins
Am J Physiol Gastrointest Liver Physiol, August 1, 2009; 297(2): G323 - G332.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. A. Permana, W. Zhang, M. Wabitsch, P. Fischer-Posovszky, W. C. Duckworth, and P. D. Reaven
Pioglitazone reduces inflammatory responses of human adipocytes to factors secreted by monocytes/macrophages
Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1076 - E1084.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. Sevillano, J. de Castro, C. Bocos, E. Herrera, and M. P. Ramos
Role of Insulin Receptor Substrate-1 Serine 307 Phosphorylation and Adiponectin in Adipose Tissue Insulin Resistance in Late Pregnancy
Endocrinology, December 1, 2007; 148(12): 5933 - 5942.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
G. Murdolo, A. Hammarstedt, M. Sandqvist, M. Schmelz, C. Herder, U. Smith, and P.-A. Jansson
Monocyte Chemoattractant Protein-1 in Subcutaneous Abdominal Adipose Tissue: Characterization of Interstitial Concentration and Regulation of Gene Expression by Insulin
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2688 - 2695.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
R. C. Reddy, Y. Hao, S.-H. Lee, S. R. Gangireddy, C. Owyang, and M. J. DiMagno
Pioglitazone reverses insulin resistance and impaired CCK-stimulated pancreatic secretion in eNOS(-/-) mice: therapy for exocrine pancreatic disorders?
Am J Physiol Gastrointest Liver Physiol, July 1, 2007; 293(1): G112 - G120.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
F Sentinelli, E Filippi, M G Cavallo, S Romeo, M Fanelli, and M G Baroni
The G972R variant of the insulin receptor substrate-1 gene impairs insulin signaling and cell differentiation in 3T3L1 adipocytes; treatment with a PPAR{gamma} agonist restores normal cell signaling and differentiation
J. Endocrinol., February 1, 2006; 188(2): 271 - 285.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
O. S. Gardner, B. J. Dewar, and L. M. Graves
Activation of Mitogen-Activated Protein Kinases by Peroxisome Proliferator-Activated Receptor Ligands: An Example of Nongenomic Signaling
Mol. Pharmacol., October 1, 2005; 68(4): 933 - 941.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
H. K.R. Karlsson, K. Hallsten, M. Bjornholm, H. Tsuchida, A. V. Chibalin, K. A. Virtanen, O. J. Heinonen, F. Lonnqvist, P. Nuutila, and J. R. Zierath
Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study
Diabetes, May 1, 2005; 54(5): 1459 - 1467.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
U. Kintscher and R. E. Law
PPAR{gamma}-mediated insulin sensitization: the importance of fat versus muscle
Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E287 - E291.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]


Home page
HypertensionHome page
S. C. Benson, H. A. Pershadsingh, C. I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M. A. Avery, and T. W. Kurtz
Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR{gamma}-Modulating Activity
Hypertension, May 1, 2004; 43(5): 993 - 1002.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
H.-i. Kim and Y.-h. Ahn
Role of Peroxisome Proliferator-Activated Receptor-{gamma} in the Glucose-Sensing Apparatus of Liver and {beta}-Cells
Diabetes, February 1, 2004; 53(90001): S60 - 65.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
V. Rotter, I. Nagaev, and U. Smith
Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-{alpha}, Overexpressed in Human Fat Cells from Insulin-resistant Subjects
J. Biol. Chem., November 14, 2003; 278(46): 45777 - 45784.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
M. M. Meyer, K. Levin, T. Grimmsmann, N. Perwitz, A. Eirich, H. Beck-Nielsen, and H. H. Klein
Troglitazone Treatment Increases Protein Kinase B Phosphorylation in Skeletal Muscle of Normoglycemic Subjects at Risk for the Development of Type 2 Diabetes
Diabetes, September 1, 2002; 51(9): 2691 - 2697.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
G. Jiang, Q. Dallas-Yang, Z. Li, D. Szalkowski, F. Liu, X. Shen, M. Wu, G. Zhou, T. Doebber, J. Berger, et al.
Potentiation of Insulin Signaling in Tissues of Zucker Obese Rats After Acute and Long-Term Treatment With PPAR{gamma} Agonists
Diabetes, August 1, 2002; 51(8): 2412 - 2419.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Y. Tamori, J. Masugi, N. Nishino, and M. Kasuga
Role of Peroxisome Proliferator-Activated Receptor-{gamma} in Maintenance of the Characteristics of Mature 3T3-L1 Adipocytes
Diabetes, July 1, 2002; 51(7): 2045 - 2055.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. Walczak and P. Tontonoz
PPARadigms and PPARadoxes: expanding roles for PPAR{gamma} in the control of lipid metabolism
J. Lipid Res., February 1, 2002; 43(2): 177 - 186.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
Y.-B. Kim, T. P. Ciaraldi, A. Kong, D. Kim, N. Chu, P. Mohideen, S. Mudaliar, R. R. Henry, and B. B. Kahn
Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110{beta} Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects
Diabetes, February 1, 2002; 51(2): 443 - 448.
[Abstract] [Full Text] [PDF]


Home page
British Journal of Diabetes & Vascular DiseaseHome page
U. Smith
Thiazolidinedione-induced effects beyond glycaemic control
The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1_suppl): S24 - S27.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by The Federation of American Societies for Experimental Biology.